Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 4,661 shares, an increase of 9,222.0% from the May 31st total of 50 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ? days.
Innate Pharma Price Performance
Shares of IPHYF stock remained flat at $1.65 during trading hours on Thursday. Innate Pharma has a 52 week low of $1.37 and a 52 week high of $2.25. The stock has a 50-day simple moving average of $1.70 and a 200-day simple moving average of $1.89.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
Featured Articles
- Five stocks we like better than Innate Pharma
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
